← BAYER (BAYRY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BAYER (BAYRY)
Healthcare · market cap $55.5B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Bayer AG (BAYRY) is a diversified global healthcare and life-science conglomerate with 88,502 employees and a market cap of approximately $42.5B. The company carries a broad late-stage pipeline spanning cardiovascular, renal, oncology, and consumer health, with several Phase 3 catalysts expected in 2026–2027. Key near-term binary events include Phase 3 data for BAY3723113 (August 2026) and BAY2927088 (February 2027), alongside a high-importance Phase 3 readout for Finerenone (Kerendia) in CKD by May 2027.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Association of darolutamide and EBRTimp 7/10
- 2027-02-15 (est.)Phase 2 · FOLFOX chemotherapy with oxaliplatinimp 7/10
- 2027-03-15 (est.)Phase 3 · bemdaneprocelimp 9/10
- 2027-03-31 (est.)Phase 2 · Finerenone Oral Tabletimp 7/10
- 2027-04-01 (est.)Phase 3 · Docetaxel 75 mg/m2imp 9/10
- 2027-04-10 (est.)Phase 3 · Finerenone (Kerendia, BAY94-8862)imp 9/10
- 2027-04-15 (est.)Phase 2 · Sorafenibimp 7/10
- 2027-05-01 (est.)Phase 2 · Regorafenib (CT)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| R-CHOP Chemotherapy | Phase 2 | Diffuse Large B Cell Lymphoma |
| Regorafenib (CT) | Phase 2 | Colorectal Cancer |
| Larotrectinib monotherapy | Phase 2 | Differentiated Thyroid Cancer |
| BAY 3670549 | Phase 2 | Atrial Fibrillation |
| GM-CSF, sargramostim | Phase 2 | Ovarian Cancer |
| bemdaneprocel | Phase 3 | Parkinsons Disease (PD) |
| GM-CSF (Sargramostim) | Phase 2 | Leukemia |
| D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV | Phase 3 | Acute Coronary Syndrome |
| Cipro XR (Ciprofloxacin, BAYQ3939) | Phase 3 | Urinary Tract Infection |
| Dabigatran | Phase 3 | Hematoma |
| Finerenone (Kerendia, BAY94-8862) | Phase 3 | Chronic Kidney Disease |
| Oxybutynin (Oxytrol, BAY839380) | Phase 3 | Overactive Bladder |
| Amikacin Inhalation Solution (BAY41-6551) | Phase 3 | Pneumonia, Bacterial |
| Darbepoetin | Phase 2 | Anemia |
| Naproxen gel | Phase 2 | Soft Tissue Injury |
| Amikacin (BAY41-6551) | Phase 2 | Pneumonia |
| BAY94-8862 | Phase 2 | Diabetic Nephropathies |
| Regorafenib (Stivarga, BAY73- 4506) | Phase 3 | Colorectal Neoplasms |
| EE20/DRSP (YAZ, BAY86-5300) | Phase 3 | Oral Contraceptive |
| Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine | Phase 3 | Common Cold |
Price & technical context
3-month
-16.2%
6-month
+9.7%
12-month
+46.3%
52-wk range
$7.56–$15.19
vs 50-day MA
-9.1%
vs 200-day MA
+3.0%
Realized vol
45.8%
Max drawdown
-42.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BAYRY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.